We are focused on developing and delivering innovative therapies that provide hope and healing for patients living with cancer. The company is conducting a pivotal clinical trial of its lead drug candidate, galeterone, in patients with metastatic castration resistant prostate cancer (mCRPC) whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor that has been associated with non-responsiveness to commonly-used oral therapies for mCRPC. This trial is the first precision medicine-based pivotal clinical trial in prostate cancer, and top-line data from the study are expected by the end of 2016.Read More
Tokai’s lead product candidate is galeterone, a highly-selective, oral small molecule with the potential to transform the treatment of prostate cancer.
We are focusing our late-stage development of galeterone on the treatment of men with metastatic, castration-resistant prostate cancer, whose prostate tumor cells express the AR-V7 splice variant. We are collaborating with Qiagen to develop and commercialize an AR-V7 companion diagnostic test for use with galeterone.